Eurofins Technologies Launches a New Multiplex RT-PCR Assay for Combined SARS-CoV-2 Screening and Rapid Detection of the Omicron (B.1.1.529) Variant of Concern
Eurofins Technologies (Paris:ERF) announces the launch of the multiplex RT-PCR assay GSD NovaType Detect + Select K417N SARS-CoV-2. Within just one week since the first reports on the Omicron variant of concern, this kit has been developed as a quick response to identify its presence. The assay is designed for the simultaneous qualitative detection of SARS-CoV-2 genomic RNA and identification of the spike (S) mutation K417N in one reaction.
The results of this RT-PCR assay can be obtained within 1 hour, which makes it a fast and cost-effective solution to identifying the presence of the Omicron variant before samples are confirmed by whole genome sequencing.
Eurofins Technologies is constantly working to adapt its product offering to meet the challenges of the ongoing COVID-19 pandemic..
For more information, please visit Eurofins Technologies website.
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005288/en/
Contact information
Rodrigo Berlie
ir@eurofins.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ExaGrid Announces All Flash/SSD Tiered Backup Storage Solution22.1.2026 15:00:00 EET | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it is shipping an All Flash/SSD backup storage solution with a unique front-end Landing Zone and non-network-facing Repository Tier (tiered air gap) that stores all backup retention using advanced data deduplication. The new SSD appliances ship with ExaGrid software version 8. ExaGrid’s unique Landing Zone and scale-out architecture allow for significantly faster backups and restores, as well as scalability as data grows, versus other SSD products such as Dell Data Domain inline deduplication appliances with SSD or straight SSD from Pure Storage. Due to three years of software work and the extremely fast performance of SSD, ExaGrid’s new SSD appliance models require a much smaller Landing Zone than on its HDD systems greatly redu
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 15:00:00 EET | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival (OS) primary endpoint. In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35 percent reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio: 0.65; p-value: 0.0004). The median OS for patients receiving relacorilant was 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone, a difference of 4.1 months. Relacorilant in combination with nab-paclitaxel was well-tolerated, consistent with its known safety profile. Importantly, the
Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis22.1.2026 15:00:00 EET | Press release
Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker™. The new functionality complements Parse’s existing portfolio of Evercode immune products to enable a full end-to-end workflow for researchers. Immunologists have lacked an integrated, purpose-built platform capable of connecting immune repertoire data with whole transcriptome single cell insights. As a result, interpreting clonal behavior, understanding functional cell states, and drawing meaningful biological conclusions has often required stitching together fragmented tools, custom code, or inconsistent visualization approaches. The new Trailmaker functionality directly addresses these challenges by providing an accessible, end-to-end immune profiling solution that brings repertoire and transcriptional information together in a cohesi
BitGo Holdings Celebrates its Debut as a Public Company on the New York Stock Exchange22.1.2026 15:00:00 EET | Press release
BitGo Holdings, Inc. (“BitGo”, the “Company”, “we”), the digital asset infrastructure company, today celebrates its debut on the New York Stock Exchange (“NYSE”) as a publicly traded company under the ticker symbol “BTGO”. Members of BitGo’s leadership team will be ringing the NYSE Opening Bell today at 9:30am ET. “Today marks a defining moment for BitGo,” said Mike Belshe, CEO and Co-Founder of BitGo. “Our entry into the public markets will enable us to further accelerate the financial system’s transition toward a transparent and credible digital asset economy, while continuing to deliver exceptional security, custody and liquidity solutions for our clients. We believe that the opportunity ahead is significant and that we are uniquely positioned to help institutions navigate the road ahead.” Belshe continued, “I am incredibly proud of the company we’ve built, and deeply grateful to our team for their hard work and dedication in reaching this milestone. As we take this next step into t
AMGTA Announces EOS as New Principal Member and Appoints Björn Hannappel to Board of Directors22.1.2026 14:59:00 EET | Press release
The Additive Manufacturer Green Trade Association (AMGTA) today announced that EOS has elevated its longstanding participation in the association to Principal Member. As part of this expanded leadership role, Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121601881/en/ Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. Principal Membership represents AMGTA’s highest level of engagement and is reserved for organizations demonstrating sustained leadership, strategic alignment, and a commitment to advancing sustainable and resilient manufacturing practices globally. As a Principal Member, EOS will take on an expanded role in shaping AMGTA’s strategic direction, governance, and industry collaboration initiatives. EOS is a world-leading technology supplier in the field of commercial 3D printing of meta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom